In accordance with recent studies it is to observe that a substantial proportion of life sciences enterprises, roughly 75%, have acknowledged digital pathology as a pivotal investment imperative for propelling the frontier in pharmaceutical research and development (R&D). What appears paradoxical is the fact that, in an era witnessing escalating application of artificial intelligence (AI) to accelerate the genesis of trailblazing therapeutics, more than half of these establishments, around 53%, persist in their utilization of antiquated legacy software systems chiefly for rudimentary image viewing.

The “2023 Life Sciences Digital Pathology Adoption Survey”, soliciting insights from 40 C-suite executives hailing from prominent pharmaceutical corporations and elite contract research organizations (CROs), sought to gauge their usage of digital pathology, the advantages it has conferred, and its prospective influences. The collated outcomes collectively underscore a burgeoning necessity to harmonize teams, applications – notably AI – and pathology data within a contemporary software infrastructure that underpins all phases of R&D within the interconnected corporate entity.